A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
A Post Marketing Surveillance of Jakavi® (Ruxolitinib) in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
Novartis Pharmaceuticals
127 participants
Apr 7, 2023
OBSERVATIONAL
Conditions
Summary
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients
Eligibility
Inclusion Criteria2
- Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label
- Patients who are willing to provide written informed consent prior to study enrollment
Exclusion Criteria3
- Patients under 12 years old
- Patients with contraindication according to locally approved label of Jakavi®
- Patients who receive or are going to receive any investigational medicine during the observation period.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05621733